Nov 14, 2024 · We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other diseases caused by dysfunction of …

12 hours ago · Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

14 hours ago · Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

17 hours ago · Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes ...

1 day ago · Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as ...

We have developed a platform prodrug technology that adds a small linker to a known or novel kinase inhibitor and suppresses on-dosing side effects common to drugs in this class, particularly gastrointestinal disturbance (nausea, diarrhea and/or vomiting).

Oct 21, 2024 · Inhibikase's multi-therapeutic pipeline includes its neurodegenerative disease portfolio led by risvodetinib in Parkinson’s disease, Multiple System Atrophy and other diseases that may arise from alpha-synuclein aggregate formation.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's ...

Mar 20, 2024 · At the 2024 AD/PD Meeting, held March 5-9, in Lisbon, Portugal, Inhibikase presented an update on its phase 2 study, Trial 201 (NCT05424276), assessing its investigational agent risvodetinib as a potential therapy for Parkinson disease (PD).

(Reuters) - Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks ...